Vir Biotechnology Appoints Timothy Coughlin as New Director and Audit Committee Chair
Summary
Vir Biotechnology appointed Timothy Coughlin, a CPA, to its Board of Directors and as Chair of the Audit Committee, enhancing financial oversight.
Key Events
-
Board Expansion
The Board of Directors increased its size from seven to eight members.
-
New Director Appointment
Timothy Coughlin, a CPA, was appointed as a Class III director, effective immediately, to serve until the 2028 annual meeting.
-
Audit Committee Chair
Mr. Coughlin was also appointed as Chair of the Audit Committee of the Board.
-
Compensation Details
As a non-employee director, Mr. Coughlin will receive standard cash and equity compensation, including stock option and restricted stock unit awards.
Analysis
Vir Biotechnology has expanded its Board of Directors and appointed Timothy Coughlin, a CPA, to fill the new vacancy and chair the Audit Committee. This move strengthens the company's corporate governance and financial oversight, bringing additional expertise to a critical board function.
At the time of this filing, VIR was trading at $7.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $4.16 to $11.66. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.